BR112013025549A2 - sais de 2,3-hidroimidazo[1,2-c]quinazolina substituídos - Google Patents

sais de 2,3-hidroimidazo[1,2-c]quinazolina substituídos

Info

Publication number
BR112013025549A2
BR112013025549A2 BR112013025549A BR112013025549A BR112013025549A2 BR 112013025549 A2 BR112013025549 A2 BR 112013025549A2 BR 112013025549 A BR112013025549 A BR 112013025549A BR 112013025549 A BR112013025549 A BR 112013025549A BR 112013025549 A2 BR112013025549 A2 BR 112013025549A2
Authority
BR
Brazil
Prior art keywords
dihydrochloride salt
cancer
prophylaxis
treatment
hydroimidazo
Prior art date
Application number
BR112013025549A
Other languages
English (en)
Portuguese (pt)
Inventor
Hans-Christian Militzer
Hartwig Müller
Jan Georg Peters
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43984137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013025549(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of BR112013025549A2 publication Critical patent/BR112013025549A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013025549A 2011-04-05 2012-03-29 sais de 2,3-hidroimidazo[1,2-c]quinazolina substituídos BR112013025549A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11161111A EP2508525A1 (en) 2011-04-05 2011-04-05 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
PCT/EP2012/055600 WO2012136553A1 (en) 2011-04-05 2012-03-29 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

Publications (1)

Publication Number Publication Date
BR112013025549A2 true BR112013025549A2 (pt) 2016-12-27

Family

ID=43984137

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013025549A BR112013025549A2 (pt) 2011-04-05 2012-03-29 sais de 2,3-hidroimidazo[1,2-c]quinazolina substituídos

Country Status (42)

Country Link
US (2) US10383876B2 (cg-RX-API-DMAC7.html)
EP (2) EP2508525A1 (cg-RX-API-DMAC7.html)
JP (2) JP5763834B2 (cg-RX-API-DMAC7.html)
KR (1) KR101937501B1 (cg-RX-API-DMAC7.html)
CN (1) CN103649091B (cg-RX-API-DMAC7.html)
AP (1) AP3709A (cg-RX-API-DMAC7.html)
AR (1) AR085718A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012238891B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013025549A2 (cg-RX-API-DMAC7.html)
CA (1) CA2832123C (cg-RX-API-DMAC7.html)
CL (1) CL2013002870A1 (cg-RX-API-DMAC7.html)
CO (1) CO6781534A2 (cg-RX-API-DMAC7.html)
CR (1) CR20130511A (cg-RX-API-DMAC7.html)
CU (1) CU24208B1 (cg-RX-API-DMAC7.html)
CY (1) CY1116231T1 (cg-RX-API-DMAC7.html)
DK (1) DK2694508T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2013000223A (cg-RX-API-DMAC7.html)
EA (1) EA023646B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP13013006A (cg-RX-API-DMAC7.html)
ES (1) ES2529653T3 (cg-RX-API-DMAC7.html)
GT (1) GT201300234A (cg-RX-API-DMAC7.html)
HR (1) HRP20150138T1 (cg-RX-API-DMAC7.html)
IL (1) IL228561A (cg-RX-API-DMAC7.html)
JO (1) JO2958B1 (cg-RX-API-DMAC7.html)
MA (1) MA35014B1 (cg-RX-API-DMAC7.html)
ME (1) ME02021B (cg-RX-API-DMAC7.html)
MX (1) MX336057B (cg-RX-API-DMAC7.html)
MY (1) MY169452A (cg-RX-API-DMAC7.html)
PE (1) PE20141038A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013502065A1 (cg-RX-API-DMAC7.html)
PL (1) PL2694508T3 (cg-RX-API-DMAC7.html)
PT (1) PT2694508E (cg-RX-API-DMAC7.html)
RS (1) RS53811B1 (cg-RX-API-DMAC7.html)
SG (1) SG193595A1 (cg-RX-API-DMAC7.html)
SI (1) SI2694508T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201500037B (cg-RX-API-DMAC7.html)
TN (1) TN2013000401A1 (cg-RX-API-DMAC7.html)
TW (2) TWI592158B (cg-RX-API-DMAC7.html)
UA (1) UA111604C2 (cg-RX-API-DMAC7.html)
UY (1) UY33985A (cg-RX-API-DMAC7.html)
WO (1) WO2012136553A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201307105B (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
AP2015008750A0 (en) 2013-04-08 2015-09-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
KR20160019434A (ko) 2013-06-14 2016-02-19 바이엘 파마 악티엔게젤샤프트 항-tweakr 항체 및 그의 용도
CN103694319B (zh) * 2013-12-20 2018-02-27 深圳翰宇药业股份有限公司 一种布舍瑞林的纯化方法
EP3018131A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016142313A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EA201791974A1 (ru) * 2015-03-09 2018-05-31 Байер Фарма Акциенгезельшафт Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин
JP6815329B2 (ja) 2015-03-23 2021-01-20 バイエル ファーマ アクチエンゲゼルシャフト 抗ceacam6抗体およびその使用
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
TN2018000271A1 (en) 2016-02-01 2020-01-16 Bayer Pharma AG Copanlisib biomarkers.
TN2018000272A1 (en) 2016-02-01 2020-01-16 Bayer Pharma AG Copanlisib biomarkers
MY199595A (en) 2016-03-02 2023-11-08 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
WO2017153220A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
WO2018054782A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
AU2017376766A1 (en) 2016-12-14 2019-06-06 Tva (Abc), Llc HSP90-targeting conjugates and formulations thereof
CA3054249A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-pd-1 antibody
CA3068324A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
WO2019048527A1 (en) 2017-09-08 2019-03-14 Bayer Pharma Aktiengesellschaft COPANLISIB FORMULATIONS
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
US20210187134A1 (en) 2018-08-28 2021-06-24 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
EP3866805A1 (en) 2018-10-16 2021-08-25 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
JP2022505325A (ja) * 2018-10-17 2022-01-14 サンド・アクチエンゲゼルシヤフト レボチロキシン及びジカルボン酸を含む共結晶
US12139491B2 (en) * 2018-12-27 2024-11-12 Holosmedic Diketopiperazine derivatives as calcium ATPase inhibitor for enhancing anticancer activity
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
WO2023218032A1 (en) 2022-05-13 2023-11-16 Synthon B.V. Solid forms of copanlisib salts
WO2025053315A1 (ko) * 2023-09-08 2025-03-13 파로스젠 주식회사 항암제 프로드러그 컨쥬게이트의 제조에서 팔라듐의 회수 및 제거 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH605550A5 (cg-RX-API-DMAC7.html) 1972-06-08 1978-09-29 Research Corp
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
TW225528B (cg-RX-API-DMAC7.html) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB0021865D0 (en) 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
WO2004029055A1 (en) * 2002-09-30 2004-04-08 Bayer Pharmaceuticals Corporation Fused azole-pyrimidine derivatives
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CA2713388C (en) 2008-01-14 2016-03-29 William Scott Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2168582A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
EA201201414A8 (ru) 2010-04-16 2013-12-30 Байер Интеллектчуал Проперти Гмбх КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
AP2015008750A0 (en) * 2013-04-08 2015-09-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
CN105934256B (zh) 2013-12-03 2019-12-27 拜耳制药股份公司 Pi3k-抑制剂的组合产品
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016142313A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EA201791974A1 (ru) 2015-03-09 2018-05-31 Байер Фарма Акциенгезельшафт Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин

Also Published As

Publication number Publication date
ECSP13013006A (es) 2013-12-31
DOP2013000223A (es) 2013-11-15
SI2694508T1 (sl) 2015-03-31
EA023646B1 (ru) 2016-06-30
CN103649091B (zh) 2016-06-22
CY1116231T1 (el) 2017-02-08
JP5763834B2 (ja) 2015-08-12
US20160193219A1 (en) 2016-07-07
JO2958B1 (en) 2016-03-15
NZ616198A (en) 2015-09-25
UY33985A (es) 2012-10-31
TN2013000401A1 (en) 2015-03-30
CN103649091A (zh) 2014-03-19
TW201249847A (en) 2012-12-16
ME02021B (me) 2015-05-20
IL228561A (en) 2015-10-29
EA201391470A1 (ru) 2014-03-31
CR20130511A (es) 2013-12-04
MX336057B (es) 2016-01-07
CU20130133A7 (es) 2014-01-29
US20140072529A1 (en) 2014-03-13
EP2694508A1 (en) 2014-02-12
ES2529653T3 (es) 2015-02-24
CU24208B1 (es) 2016-11-29
PH12013502065A1 (en) 2016-06-29
TWI592158B (zh) 2017-07-21
CA2832123A1 (en) 2012-10-11
IL228561A0 (en) 2013-12-31
RS53811B1 (sr) 2015-06-30
WO2012136553A1 (en) 2012-10-11
EP2508525A1 (en) 2012-10-10
AU2012238891A1 (en) 2013-10-24
HRP20150138T1 (hr) 2015-05-08
UA111604C2 (uk) 2016-05-25
MA35014B1 (fr) 2014-04-03
US9636344B2 (en) 2017-05-02
JP2015164936A (ja) 2015-09-17
HK1195907A1 (zh) 2014-11-28
AP3709A (en) 2016-05-31
US10383876B2 (en) 2019-08-20
KR101937501B1 (ko) 2019-01-10
TWI549954B (zh) 2016-09-21
DK2694508T3 (en) 2015-02-16
EP2694508B1 (en) 2014-11-19
CA2832123C (en) 2018-09-11
SG193595A1 (en) 2013-10-30
PE20141038A1 (es) 2014-09-05
PT2694508E (pt) 2015-02-10
CL2013002870A1 (es) 2014-06-20
ZA201307105B (en) 2014-11-26
PL2694508T3 (pl) 2015-04-30
AP2013007219A0 (en) 2013-10-31
SMT201500037B (it) 2015-05-05
TW201637656A (zh) 2016-11-01
AU2012238891B2 (en) 2016-12-01
AR085718A1 (es) 2013-10-23
JP5826961B2 (ja) 2015-12-02
MY169452A (en) 2019-04-11
GT201300234A (es) 2015-01-16
CO6781534A2 (es) 2013-10-31
JP2014510119A (ja) 2014-04-24
KR20140021637A (ko) 2014-02-20
MX2013011583A (es) 2013-12-16

Similar Documents

Publication Publication Date Title
TN2013000401A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
TR201807411T4 (tr) DNA-PK inhibitörleri.
CY1119714T1 (el) Ενωσεις αναστολεων
FI3574904T3 (fi) B-raf-inhibiittoria, egfr-inhibiittoria ja valinnaisesti pi3k-alfa-inhibiittoria käsittäviä farmaseuttisia koostumuksia
BR112013029246A2 (pt) 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico
GB201104267D0 (en) Pyrrolopyridineamino derivatives
NZ710636A (en) Heterocyclic compounds and uses thereof
BR112015007586A2 (pt) derivados de pirrolo[3,2-d]pirimidina para o tratamento de infecções virais e outras doenças
PH12018500532A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
EA201492125A1 (ru) НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2
BR112012027197A2 (pt) combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas
BR112012026289A2 (pt) composto orgânico para uso no tratamento de câncer do fígado
EA201291098A1 (ru) Новые соединения 3,5-дизамещенного-3h-имидазо[4,5-b]пиридина и 3,5-дизамещенного -3h-[1,2,3]триазоло[4,5-b]пиридина как модуляторы протеинкиназ
BR112015012693A2 (pt) derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral
EP1951729A4 (en) OXYGEN-BOUND PYRIMIDINE DERIVATIVES
BR112014029708A2 (pt) composto de pirrolo[2,1-f][1,2,4]triazina, método de preparação de compostos de pirrolo[2,1-f][1,2,4]triazina e uso do composto de pirrolo[2,1-f][1,2,4]triazina
MX2015002044A (es) Pirazolil-ureas como inhibidores de quinasa.
EA201500826A1 (ru) Содержащая альбуминсвязывающую аргининдезиминазу фармацевтическая композиция для таргетной терапии рака
MY202114A (en) Treatment of brain cancer
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
BR112013033544A2 (pt) dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos
MY158693A (en) Formulation comprising phenylaminopyrimidine derivative as active agent
MX2012013527A (es) Quinazolinas policíclicas, preparación de las mismas, y uso de las mismas.
BR112014005653A2 (pt) uso de 4-amino-5-fluoro-3[6-(4-metilpiperazin-1-il)-1h-benzimidazol-2-1l]1h-quinolin-ona no tratamento de câncer de em pacientes com insuficiência hepática moderada
BR112014016632A8 (pt) uso terapêutico de derivados de imidazopiridina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B65X Notification of requirement for priority examination of patent application
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]